Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
3.
Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence.
Am J Pathol
; 193(1): 51-59, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243045
4.
CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights.
Blood
; 140(13): 1461-1469, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560330
5.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
6.
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 194(4): 690-700, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34296427
7.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Blood
; 134(13): 1024-1036, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331917
8.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850381
9.
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
BMC Infect Dis
; 21(1): 72, 2021 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33446136
10.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528286
11.
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med
; 377(26): 2531-2544, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226797
12.
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Am J Hematol
; 95(1): 18-27, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31621094
13.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(1): 31-42, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30518502
14.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241979
15.
A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs.
Oncologist
; 24(1): 76-85, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266893
16.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica
; 109(1): 343-350, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470152
17.
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
Haematologica
; 109(3): 953-957, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706336
18.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res
; 36(7): 93, 2019 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044267
19.
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Cancer
; 124(12): 2561-2569, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723393
20.
Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood
; 127(12): 1559-63, 2016 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26764355